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ABSTRACT
The UK’s National Institute for Health and Care Excellence 
Preterm labour and birth guideline recommends use of 
magnesium sulfate (MgSO4) in deliveries below 30 weeks’ 
gestation to prevent cerebral palsy and other neurological 
problems associated with preterm delivery. Despite 
national guidance, the uptake of MgSO
4 administration in 
eligible women has been slow. National Health Service 
England has rolled out the PReCePT (PRevention of 
Cerebral Palsy in Pre- Term labour) quality improvement 
(QI) toolkit to increase uptake of MgSO
4 in preterm 
deliveries. The toolkit is designed to increase maternity 
staff knowledge about MgSO4 and provides training 
and practical tools to help staff consider use in eligible 
women. The PReCePT trial compares the effectiveness 
of two different methods of implementing the QI toolkit 
(standard versus enhanced support). The standard support 
arm (control) receives the QI toolkit and regional- level 
support for a midwife/obstetric ‘champion’. The enhanced 
support arm (intervention) receives this plus additional 
clinical backfill funding and unit- level QI microcoaching. 
It is funded by The Health Foundation. This is a cluster 
randomised controlled trial designed to include 48 
maternity units randomised (2:1 ratio) to standard or 
enhanced support. Units are eligible for inclusion if they 
have 10 or more preterm (<30 weeks’ gestation) deliveries 
annually and MgSO
4 uptake of 70% or less. Randomisation 
is stratified by previous level of MgSO4 uptake. The QI 
intervention is implemented over 9 months. All units are 
followed up for a further 9 months. Blinding is not possible 
due to the nature of the intervention. The primary outcome 
is the proportion of MgSO
4 uptake among eligible women 
at follow- up, adjusting for uptake before implementation 
of the toolkit. The effectiveness of the intervention will be 
assessed using weighted linear regression on data from 
the National Neonatal Research Database. Semistructured 
qualitative staff interviews will inform understanding of the 
process and outcomes. Economic evaluation will describe 
total costs and cost- effectiveness.
Trial registration number SRCTN 40938673.
INTRODUCTION
Preterm birth is the leading cause of neonatal 
mortality and morbidity,1 and specifically 
brain injury and cerebral palsy (CP).2–4 
Around 1% of births in high- income coun-
tries are very preterm (less than 30 weeks’ 
gestational age (GA)).5 While around 90% 
of very preterm infants survive beyond the 
postpartum period,6 it is estimated that 
approximately a third develop neurodisabil-
ities, including CP, blindness, deafness and 
cognitive impairment.7–9 Around 10% of 
very preterm births in high- income countries 
result in CP.3 6 10
Antenatal magnesium sulfate (MgSO4) 
therapy given to women at risk of preterm 
birth reduces the risk of CP in their child by 
around 30% (relative risk 0.68, 95% CI 0.54 
to 0.87).11 At under 30 weeks’ gestation, the 
number needed to treat to prevent one case 
of CP is 37 (95% CI 23 to 102).12 CP has a 
significant burden both for individuals and 
families13 and healthcare services, with an 
estimated lifetime cost per person (including 
healthcare, productivity and social costs) of 
€830 000.14 15 Approximately 1400 cases of 
brain injury among preterm babies could 
potentially be avoided by consistent adminis-
tration of MgSO4 during labour each year in 
the UK, including 200 cases of CP annually in 
England.12
Since 2015, the UK National Institute 
for Health and Care Excellence has recom-
mended administration of MgSO4 in very 
preterm deliveries as a core part of maternity 
care.16 Failure to comply with this guideline is 
considered suboptimal care. Uptake of MgSO4 
in eligible women in the UK has historically 
been low compared with the rest of the high- 
income countries.17 18 For infants below 30 
weeks’ gestation, the UK National Neonatal 
Audit reported that in 2017, only 64% of 
eligible women received MgSO4.
19 There is 
high variation in uptake between different 
regional networks (range 49%–78%).19 
While there is evidence that uptake has been 
increasing (from 9% reported in 2012),20 
















ual: first published as 10.1136/bm



















ual: first published as 10.1136/bm



















ual: first published as 10.1136/bm



















ual: first published as 10.1136/bm



















ual: first published as 10.1136/bm



















ual: first published as 10.1136/bm



















ual: first published as 10.1136/bm



















ual: first published as 10.1136/bm



















ual: first published as 10.1136/bm





2 Edwards H, et al. BMJ Open Quality 2021;10:e001204. doi:10.1136/bmjoq-2020-001204
Open access 
The PReCePT quality improvement (QI) toolkit was 
developed to increase knowledge and awareness among 
maternity unit staff about MgSO4 as a neuroprotective 
agent in preterm deliveries.21 It provided practical tools 
and training to help staff consider MgSO4 in eligible 
women. It was codesigned by clinical teams and mothers 
who had experienced preterm birth. The PReCePT pilot 
study, set in five maternity units in the West of England, 
increased the MgSO4 uptake from an average baseline of 
21% over the 2 years preceding the project to 88% by the 
end of the project.21 Improvements were observed for 
all participating units, although rates of uptake varied 
between maternity units.21
Based on the success of the PReCePT pilot, National 
Health Service (NHS) England funded a national roll 
out of the intervention (National PReCePT Programme 
(NPP)). The NPP aims to support all maternity units in 
England to increase their use of MgSO4 to 85% of eligible 
women by 2020.The NPP was rolled out by the regional 
Academic Health Science Networks (AHSNs), whose 
role is to facilitate health innovations to improve health 
outcomes.
Trial justification
The PReCePT pilot demonstrated that a QI package with 
bespoke unit- level coaching and backfill was effective in 
improving MgSO4 uptake.
21 The PreCePT package and 
implementation toolkit was refreshed, incorporating 
lessons learnt from the pilot, and a theory of change 
framework was used to define a logic model (online 
supplemental appendix 1), identifying drivers of change, 
relevant processes and outcome measured to guide eval-
uation ( www. theoryofchange. org). The implementation 
and evaluation of the trial also follow QI methodolo-
gies used in the PReCePT pilot: the model for improve-
ment and microsystems 5Ps approach.21 The NPP uses 
a reduced version of this package, more focused on 
providing resources for self- engagement. It is not clear if 
this reduced level of support will be sufficient to improve 
MgSO4 uptake to the target level. This trial compares the 
standard support as used in the NPP, with the enhanced 
support model as used in the original PReCePT pilot.
Objective
The PReCePT trial described in this protocol paper was 
designed to compare the effectiveness, cost- effectiveness 
and sustainability of the enhanced support model 
compared with the standard level of support in encour-
aging increased use of MgSO4 among eligible women. 
Comparative evidence between the two adoption models 
will inform the method of optimal future UK spread.
METHODS
Trial design
This is an open cluster randomised controlled trial set in 
NHS England maternity units. Each maternity unit is a 
‘cluster’. The two trial arms (allocation ratio 2:1 control 
to intervention) are
Control group (standard support): implementation of 
the PReCePT QI toolkit as guided by the NPP and regional 
AHSN. This includes provision of PReCePT QI materials 
(preterm labour proforma, staff training presentations, 
parent leaflet, posters for the unit and learning log22), 
regional- level QI training and support, and up to 90 
hours funded backfill per unit for the midwife champion. 
Implementation is led by local midwives and an obstetri-
cian champion, selected internally by each unit (table 1).
Intervention group (enhanced support): implemen-
tation of the PReCePT QI toolkit as for the standard 
support group, plus individual unit- level coaching by 
an experienced QI coach (a first in- person visit, a final 
in- person visit and regular telephone coaching during the 
9 months implementation phase), a computer tablet for 
micro- coaching staff, access to learning and celebration 
events, an additional 90 hours backfill funding for the 
local midwife champion, and 0.5 Programmed Activities 
(PA)/week of funded backfill for the local neonatologist 
champion. At each unit’s discretion, this 0.5 PA backfill 
can be shared between the neonatologist and obstetrician 
champion (table 1).
The trial randomisation and implementation are 
aligned with the NPP time frame as the trial is embedded 
within the NPP. The NPP is implementing the PReCePT 
QI toolkit in two waves, starting in May and September 
2018. This staggered approach is to accommodate differ-
ences in readiness of units to put logistical arrangements 
in place. The trial is aligned with these waves to maxi-
mise comparability between groups. The enhanced QI 
support will be implemented in the intervention units for 
9 months after randomisation (December 2018–August 
2019 for first- wave units, January 2019–September 2019 
for second- wave units). The trial units will have a 9- month 
follow- up period after the end of the implementation 
phase (figure 1 and online supplemental appendix 2).
Eligibility criteria
Eligibility criteria include maternity units in England 
participating in the NPP with 10 or more preterm (<30 
weeks’ gestation) deliveries annually and with MgSO4 
uptake of 70% or less. Eligibility criteria are assessed 
from National Neonatal Audit Programme (NNAP) 
data from 2017. Units that took part in the PReCePT 
pilot are excluded.
Recruitment
The study evaluation team will identify participants 
(maternity units) according to inclusion/exclusion 
criteria and obtain unit contact details and contact details 
of key staff members (lead midwife, lead obstetrician 
and lead neonatologist) from the regional Operational 
Neonatal Delivery Networks and AHSNs. Unit eligibility 
for the trial will be confirmed by the study statisticians.
Consent
Written informed unit- level consent is required for 
participation. The clinical service lead for maternity and 
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invitation letter, unit information sheet describing the 
project and consent form (Appendix 3a). On the advice 
of the UK NHS Health Research Authority, consent was 
not obtained from individual women. This is because at 
the patient- level, only anonymous routinely collected data 
are used, and clinical guidance on the appropriate care 
for each individual woman is unaffected by either trial 
arm, or even whether or not their hospital is taking part 
in the study. For qualitative interviews with individual unit 
staff, individual consent (Appendix 3b) will be obtained.
Withdrawal criteria
Units in the enhanced support model arm can withdraw 
at any time. They will then revert to the standard support 
model and be followed up accordingly. Their data will be 
collected and included as planned and analysed according 
Table 1 Trial groups
Control (group 1, standard support) Intervention (group 2, enhanced support)
PReCePT QI toolkit Clinical guidance; preterm labour proforma 
template; staff training presentations;
parent leaflet; posters for display on the unit 
to raise staff awareness; a QI learning log; 
project dashboard; pens, magnets, lanyards 
and other aide- mémoires to promote MgSO4 
to unit staff (if purchased)
As per standard support group
QI training Regional- level QI training and guidance to 
adapt materials for local use, cascaded from 
AHSN
As per standard support group
Regional support Support from a regional level neonatal lead 
and AHSN lead
As per standard support group
Local obstetrician 
champion
Local obstetrician identified by unit to guide 
and oversee local implementation
As per standard support group (named as joint PI, at 
discretion of local site)
Funded time for local 
midwife champion
Funded time of up to 90 hours per unit (on 
average 2 hours/week)
As per standard support, plus funding for up to 90 extra 
hours backfill, on average over 12 months, to enable the 
midwife to embed the QI toolkit within their team
Funded time for local 
neonatologist champion
None Funded time for a local neonatologist Principal Investigator 
(PI), working on average 0.5 Programmed Activities (PA, 
2 hours) per week over 12 months, to provide clinical 
leadership in local unit (fixed- term contract or secondment 
from an National Health Service organisation)
0.5 PA backfill may be split with obstetrician PI, at discretion 
of local site
QI coaching None Structured coaching in local unit from an experienced QI 
coach. To include
first visit where the QI coach will work with local unit to 
create a bespoke implementation plan; telephone coaching 
in liaison with the local champion(s), with occasional face- 
to- face visits as logistics permit; ongoing dedicated support 
to help embed the QI toolkit within local unit; final visit to 
support local unit to tie- up data collection and plan for 
ongoing sustainability
Learning events None Funding for up to three members of staff from local unit 
to attend three learning events These bespoke learning 
events will be held every 2–3 months during the period of 
implementation and will bring together teams from other 
group 2 units to share their activity and learning on how they 
are implementing the PReCePT QI toolkit and working to 
address issues and challenges.
Celebration event None Provision of an android tablet to be used by the local 
midwife champion to microcoach colleagues, plus a small 
fund for purchasing study collateral (pens, magnets, lanyards 
and aide- mémoires), if required
Collateral funding None Funding for up to three members of staff from local unit to 
attend a celebration event which will bring together teams 
from all group 2 units to wrap up the study and to share 
experiences, learning and success
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to trial allocation (intention to treat). An exit interview 
will be requested to assess reasons for withdrawal. Staff 
participating in interviews can withdraw at any time, and 
if they do, their data will not be used in analysis.
Sample size
The sample size of the enhanced support group is limited 
to 16 maternity units to fit within the trial budget. Based 
on results from the PReCePT pilot study21 and 2016 NNAP 
data, we anticipate MgSO4 uptake of approximately 38% 
and 80% in the two trial arms. With a two- sided 5% signif-
icance level, this study will have 86% power to detect an 
absolute difference of 40 percentage points in MgSO4 
uptake at follow- up between the control and interven-
tion groups (based on a 2:1 randomisation ratio). As the 
planned analysis is at the cluster (maternity unit) level, 
this removes any clustering effects that could impact on 
sample size calculations. National Neonatal Registry Data-
base (NNRD) data report that during 2017, the target 48 
maternity units had a mean of 30 preterm births (IQR 
14–41).
Randomisation
Maternity units are the units of randomisation. Of the 
eligible and consenting units, 48 are planned to be allo-
cated within the trial at a 2:1 ratio (ie, 32 control and 
16 intervention). Randomisation will occur in two waves 
in line with the NPP’s phased approach of starting the 
programme in two waves. In both wave 1 and wave 2, 16 
units are planned to be allocated to the standard support 
model arm, and 8 units to the enhanced support model 
arm.
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To reduce imbalance between groups, units will be strat-
ified by 2017 MgSO4 uptake rates. Stratification groups 
based on consenting units are 0%–39.9%, 40.0%–49.9%, 
50.0%–59.9% and 60.0%–70.9%. For each trial arm, four 
reserve units will be selected and included in the rando-
misation, in case of unit drop- out.
Randomisation will be performed with STATA package 
command stratarand and carried out by a statistician inde-
pendent of the trial and the NPP.
Due to the nature of the interventions, it is not possible 
to conceal the allocation to members of the research 
team and hospital staff.
Outcomes
The primary outcome for the trial is the unit- level 
uptake of MgSO4 administration among eligible women 
(preterm birth <30 weeks’ gestation) defined as whether 
or not the mother received MgSO4 prior to delivery. This 
is measured at the end of the trial and will be expressed 
as the percentage of eligible mothers receiving MgSO4 
among all eligible mothers. To enable comparison with 
national reported data, we will be using the 2017 NNAP 
method of omitting mothers with missing/not available 
MgS04 data from both the numerator and denominator. 
We will conduct a sensitivity analysis to assess whether 
there is selection bias associated with the exclusion of 
these mothers.
We will consider secondary outcomes to further eval-
uate effectiveness in other respects, as well as inves-
tigations into the process of implementation and an 
economic evaluation. For effectiveness, we will addition-
ally evaluate trend in uptake (testing for step- change/
change in trend) before, during and after implemen-
tation; longer- term trends in uptake over 2011–2019; 
reasons MgSO4 was not given in eligible women; whether 
the impact of the QI toolkit is affected when adjusting for 
potential confounding factors; whether the intervention 
was carried out as intended, staff experience and data 
quality.
To evaluate the process of implementation at each unit, 
we will explore proportion and type of staff receiving 
training; number of and time required for training 
sessions; number and size of staff meetings for feedback 
and discussion; extent of other ongoing research/QI 
projects and previous QI experience; adherence to the 
PReCePT QI toolkit; staff confidence, involvement and 
engagement; organisational factors such as restructuring, 
understaffing, changes in management; and professional 
or cultural issues that could affect implementation.
For the economic evaluation, we explore time and 
resources required in both intervention and control 
groups, cost associated with backfill for local clinical 
champions, total cost associated with each support model 
and cost- effectiveness.
Analyses
The trial will use multiple methods to evaluate the 
enhanced QI support compared with the standard 
support.
Effectiveness data collection and evaluation
We will use anonymised patient- level extracts of the UK 
NNRD from units participating in the trial.23 Data on 
MgSO4 use are collected routinely in BadgerNet, the 
clinical audit database completed by clinicians in every 
neonatal unit in England. BadgerNet data are transferred 
quarterly to the NNRD. Fields relating to the MgSO4 care 
pathway are mandatory and are regarded as good quality 
(over 70% completeness) since 2015. Data in the NNRD 
undergo multiple quality assurance procedures and are 
considered to have high accuracy and completeness.23 24
The TeamSTEPPS Teamwork Perceptions Question-
naire25 will be administered to all units in both trial arms 
at the start (months 1–3) and end of the implemen-
tation period (month 9). This measures any change in 
levels of collaborative maternity and neonatal team func-
tioning, leadership, support and communication. It will 
be completed by the three local champions at each unit 
(champion midwife, neonatologist and obstetrician) to 
get a range of perspectives on perinatal teamworking.
To compare the effectiveness of enhanced support 
versus the standard support model, we will be using 
weighted linear regression to model MgSO4 uptake at the 
end of follow- up, adjusted for baseline MgSO4 uptake. We 
will use a regression- based adjustment for baseline and 
will adjust for clustering by conducting the regression 
with the cluster (maternity unit) as the unit of analysis.26 
Baseline MgSO4 uptake is the uptake reported by the unit 
in the 12 months prior to randomisation. Postinterven-
tion MgSO4 uptake is the uptake reported by the unit at 
the end of the trial.
Multilevel mixed- effects models will be used to adjust 
for any covariates representing background differences 
between the study groups. These will include mater-
nity unit characteristics such as NPP wave (1 or 2), level 
of neonatal unit (secondary or tertiary), unit annual 
number of births, previous QI experience (all data 
collected via a baseline questionnaire), the effects of the 
AHSN structure, levels of maternal hypertension, GA at 
delivery and antenatal steroid administration (unit- level 
averages measured at baseline, data from the NNRD). 
For multiple births, in order to remain consistent with 
NNAP reporting, we will only include data on one baby 
(the first- born) from each multiple birth. The proportion 
of multiple pregnancies (single vs multiple, twin, triplet, 
etc) will be adjusted for. For describing baby- level demo-
graphics, we will include all babies from multiple births.
Multiple imputation using chained equations will 
be used to impute missing variables using the ‘ice’ 
command in STATA. Twenty datasets will be imputed 
with an imputation model including the outcome, 
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impact of missing not at random using sensitivity 
analysis.
For the intervention units only, QI coaches will also 
record monthly data on each unit’s level of engage-
ment and activity with PReCePT (both scored as at- risk, 
progressing or on- track) and risks/issues encountered. 
This will be collected as part of their regular interaction 
with each unit to deliver coaching. Multivariable linear 
regression will be used to assess whether these factors 
are associated with level of MgSO4 uptake in interven-
tion group maternity units.
Qualitative data collection and evaluation
To evaluate the implementation of the QI intervention in 
each unit (eg, level of compliance, whether it was deliv-
ered as intended, any local adaptations, any unexpected 
obstacles, the local context and staff experience), semi-
structured qualitative interviews will be conducted with 
staff. Interviews will either be face- to- face, by telephone 
or video call. These will be recorded, transcribed and 
analysed using the framework method.27
Criterion- based sampling (trial arm, number of births 
per year, baseline rate of MgSO4 uptake, recent Care 
Quality Commission ratings on units’ leadership and 
patient safety performance) will be used to select up to 20 
trial units. We will purposively sample two to three partic-
ipants at each site in the roles of midwife, obstetrician 
and/or neonatologist.
Interviews will be analysed using the framework 
method.27 The matrix output, using rows, columns and 
‘cells’ of summarised data, facilitates analysis by case 
(eg, site, professional group or individual) and by code 
(summarised data in relation to a particular theme such 
as intervention fidelity). This allows comparison of data 
across, as well as within, cases to inform an understanding 
of factors affecting implementation and observed 
outcomes.
Economic data collection and evaluation
We will conduct a policy cost- effectiveness evaluation to 
compare the cost- effectiveness of the enhanced support 
model with the standard support model.28 29
To measure resource use at each unit, we will use 
information provided by the NPP and AHSNs, and data 
collected via electronic proformas issued monthly to each 
trial unit and completed by local champions. These will 
record time spent preparing reports, at events, at staff 
training sessions, number and type of staff involved, and 
time spent receiving QI coaching/support.
Costs are estimated by multiplying the volume of 
resources used (mainly staff time) by the price of each 
resource unit (unit cost). Costs, for example, based on 
staff salary band, will be valued using national unit cost 
estimates, where available.30 Mean total implementation 
costs per unit will be estimated for both support models. 
We will categorise costs according to the different phases 
of the QI in which they occur, specifically, developmental 
costs, organising costs, executing costs and sustainability 
costs.
The incremental cost- effectiveness ratio will be calcu-
lated and shows the additional costs required to achieve 
one additional percentage point improvement of MgSO4 
uptake. Univariate sensitivity analyses will be carried 
out to evaluate the impact of assumptions and unit cost 
estimates on the results. Previous economic analyses31 32 
have estimated the long- term cost- effectiveness of MgSO4 
administration in preterm births. If enhanced support 
results in increased uptake of MgSO4 administration, 
we will use this evidence to estimate the long- term cost- 
effectiveness of enhanced support in terms of costs per 
quality adjusted life year gained.
Confidentiality
Trial staff will ensure that the unit and staff participants’ 
confidentiality is maintained through protective and 
secure handling and storage of patient information. All 
data will be collected within the maternity unit by staff as 
part of routine clinical care, and confidentiality will be 
maintained at all times. Subsequent incidence data will 
be passed to the research team from NNRD in numerical 
format and will be fully anonymised.
Units and staff participants will be anonymised in any 
publications resulting from this study. In the reporting 
of quotes in publications, non- essential details of the 
participants will be altered slightly to further prevent 
identification. If participants refer to any medical staff or 
healthcare facility by name, this will be anonymised in the 
interview transcript.
Data monitoring
As this is a QI project, data monitoring will largely be 
completed at the local level. The local neonatologist 
champion will have responsibility for monitoring data 
completion in their unit. As part of the NPP, the NHS 
National Patient Safety Measurement Unit will create a 
national dashboard demonstrating the data from Badg-
erNet on MgSO4 administration. Local units will be able 
to produce monthly reports to monitor performance. 
The trial team will also be able to monitor data collec-
tion for trial units and address any data concerns. Any 
concerns will be reported to the Trial Steering Group.
Access to the data will be managed, auditable and 
restricted to those individuals who need to process the 
data for the purposes of the study. Direct access can be 
granted to authorised representatives from the sponsor, 
host institution and the regulatory authorities to permit 
trial- related monitoring, audits and inspections.
Public and patient involvement (PPI)
PPI for the trial builds on the involvement work that took 
place in the PReCePT pilot study.21 This used a codesign 
and coproduction approach including a partnership 
with BLISS, a support organisation for mothers experi-
encing preterm births, and two mothers who had expe-
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the steering group for the project and were involved in 
trial design. People in Health West of England, a shared 
regional public involvement resource based in the West 
of England, also helped to shape the design. A reference 
group of relevant stakeholders will help guide dissemina-
tion of findings.
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Appendix 2: PReCePT Study Gantt Chart 
 
Activity 
2018 2019 2020 2021 
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 
Site Recruitment           
Wave 1            
Randomisation             
Intervention implementation               
Follow-up                
Data collection TeamSTEPPS             
Wave 2            
Randomisation             
Intervention implementation             
Follow-up            
Qualitative data collection             
Qualitative analysis             
Data collection TeamSTEPPS           
Data collection from NNRD           
Quantitative data analysis           
Health economic analysis           
Report writing            
Dissemination           
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